CytoDyn Inc. (CYDY)
OTCMKTS
· Delayed Price · Currency is USD
0.3998
+0.0737 (22.60%)
May 9, 2025, 4:00 PM EDT
CytoDyn Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
9
Market Cap
417.40M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.76B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 200.90M |
Elite Pharmaceuticals | 70.00M |
Northwest Biotherapeutics | 1.38M |
BioStem Technologies | 301.83M |
American Oncology Network | 1.76B |
CytoDyn News
- 3 days ago - CytoDyn appoints Robert Hoffman as CFO - Seeking Alpha
- 3 days ago - CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer - Benzinga
- 3 days ago - CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer - GlobeNewsWire
- 10 days ago - CytoDyn Leadership Team To Attend ESMO Breast Cancer Meeting in Munich, Germany - GlobeNewsWire
- 7 weeks ago - March 2025 Letter to Shareholders - GlobeNewsWire
- 2 months ago - CytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with Leronlimab - GlobeNewsWire
- 3 months ago - CytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with SMC Laboratories - GlobeNewsWire
- 5 months ago - December 2024 Letter to Shareholders - GlobeNewsWire